Liposome–nucleic acid immunotherapeutics

Bibliography

• Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 2003;130:180-92
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002;20:197-216
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351-3
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9
   PubMed Web of Science ®Google Scholar
• Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006;7:1266-73
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev 2007;7:31-40
   Google Scholar
• Delbridge LM, O'Riordan MX. Innate recognition of intracellular bacteria. Curr Opin Immunol 2007;19:10-16
   PubMed Web of Science ®Google Scholar
• Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006;7:1250-7
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev 2004;4:499-511
   Google Scholar
• Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80
   PubMed Web of Science ®Google Scholar
• Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 2007;19:48-55
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95
   PubMed Web of Science ®Google Scholar
• Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev 2006;6:9-20
   Google Scholar
• Peyrin-Biroulet L, Vignal C, Dessein R, Simonet M, Desreumaux P, Chamaillard M. NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. Trends Microbiol 2006;14:432-8
   PubMed Web of Science ®Google Scholar
• Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function? Immunity 2005;22:661-7
   PubMed Web of Science ®Google Scholar
• Hsu YM, Zhang Y, You Y, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 2007;8:198-205
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Eynon EE, Flavell RA. Intracellular debugging. Nat Immunol 2003;4:652-4
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003;4:702-7
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006;7:40-8
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-5
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730-7
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501-5
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006;24:93-103
   PubMed Web of Science ®Google Scholar
• Honda K, Ohba Y, Yanai H, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005;434:1035-40
   PubMed Web of Science ®Google Scholar
• Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev 2004;4:512-20
   Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Gursel I, Gursel M, Klinman DM. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr Opin Mol Ther 2004;6:166-74
   PubMed Web of Science ®Google Scholar
• Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004;199:201-16
   PubMed Web of Science ®Google Scholar
• Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995;9:927-38
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 1993;62:101-7
   PubMedGoogle Scholar
• Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm 1998;13:363-8
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:4249-58
   PubMed Web of Science ®Google Scholar
• Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995;1:1165-70
   PubMed Web of Science ®Google Scholar
• Murray JL, Kleinerman ES, Cunningham JE, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 1989;7:1915-25
   PubMed Web of Science ®Google Scholar
• Tanguay S, Bucana CD, Wilson MR, Fidler IJ, von Eschenbach AC, Killion JJ. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A. Cancer Res 1994;54:5882-8
   PubMed Web of Science ®Google Scholar
• Liu Y, Liggitt D, Zhong W, Tu G, Gaensler K, Debs R. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 1995;270:24864-70.
   PubMed Web of Science ®Google Scholar
• Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997;15:167-73
   PubMed Web of Science ®Google Scholar
• Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999;163:1552-61
   PubMed Web of Science ®Google Scholar
• Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999;6:1867-75
   PubMed Web of Science ®Google Scholar
• Whitmore MM, Li S, Falo L Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 2001;50:503-14
   PubMed Web of Science ®Google Scholar
• Lanuti M, Rudginsky S, Force SD, et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000;60:2955-63
   PubMed Web of Science ®Google Scholar
• Wilson A, Pitt B, Li S. Complex roles of CpG in liposomal delivery of DNA and oligonucleotides. Biosci Rep 2002;22:309-22
   PubMed Web of Science ®Google Scholar
• Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001;167:3324-8
   PubMed Web of Science ®Google Scholar
• Khazanov E, Simberg D, Barenholz Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J Gene Med 2006;8:998-1007
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006;176:7335-45
   PubMed Web of Science ®Google Scholar
• Wong JP, Yang H, Nagata L, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 1999;17:1788-95
   PubMed Web of Science ®Google Scholar
• Sakurai F, Terada T, Maruyama M, et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther 2003;10:661-8
   PubMed Web of Science ®Google Scholar
• Hamm S, Heit A, Koffler M, et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int Immunol 2007;19:297-304
   PubMed Web of Science ®Google Scholar
• Sellins K, Fradkin L, Liggitt D, Dow S. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol Ther 2005;12:451-9
   PubMed Web of Science ®Google Scholar
• Gowen BB, Fairman J, Smee DF, et al. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 2006;69:165-72
   PubMed Web of Science ®Google Scholar
• Moss EG, Taylor JM. Small-interfering RNAs in the radar of the interferon system. Nat Cell Biol 2003;5:771-2
   PubMed Web of Science ®Google Scholar
• Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9
   PubMed Web of Science ®Google Scholar
• de Veer MJ, Sledz CA, Williams BR. Detection of foreign RNA: implications for RNAi. Immunol Cell Biol 2005;83:224-8
   PubMed Web of Science ®Google Scholar
• Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006;58:32-45
   PubMed Web of Science ®Google Scholar
• Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta 1994;1189:195-203
   PubMed Web of Science ®Google Scholar
• Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1995;1235:296-304
   PubMed Web of Science ®Google Scholar
• Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 2002;277:18021-8
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Signaling pathways activated by microorganisms. Curr Opin Cell Biol 2007;19:185-91
   PubMed Web of Science ®Google Scholar
• Zelphati O, Szoka FC Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996;93:11493-8
   PubMed Web of Science ®Google Scholar
• Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006;203:1999-2008
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-7
   PubMed Web of Science ®Google Scholar
• Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2005;2:22-8
   PubMed Web of Science ®Google Scholar
• Niven R, Pearlman R, Wedeking T, et al. Biodistribution of radiolabeled lipid-DNA complexes and DNA in mice. J Pharm Sci 1998;87:1292-9
   PubMed Web of Science ®Google Scholar
• Ishiwata H, Suzuki N, Ando S, Kikuchi H, Kitagawa T. Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Rel 2000;69:139-48
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther 2004;3:197-204
   PubMed Web of Science ®Google Scholar
• Delepine P, Guillaume C, Montier T, et al. Biodistribution study of phosphonolipids: a class of non-viral vectors efficient in mice lung-directed gene transfer. J Gene Med 2003;5:600-8
   PubMed Web of Science ®Google Scholar
• Tranchant I, Thompson B, Nicolazzi C, Mignet N, Scherman D. Physicochemical optimisation of plasmid delivery by cationic lipids. J Gene Med 2004;6(Suppl 1):S24-S35
   PubMed Web of Science ®Google Scholar
• Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4:289-94
   PubMedGoogle Scholar
• CpG 7909: PF 3512676, PF-3512676. Drugs R D 2006;7:312-16
   PubMedGoogle Scholar
• Dow SW, Elmslie RE, Fradkin LG, et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 1999;10:2961-72
   PubMed Web of Science ®Google Scholar
• Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Rocken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000;60:1515-20
   PubMed Web of Science ®Google Scholar
• McLachlan G, Stevenson BJ, Davidson DJ, Porteous DJ. Bacterial DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to mouse lungs. Gene Ther 2000;7:384-92
   PubMed Web of Science ®Google Scholar
• Blezinger P, Freimark BD, Matar M, et al. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther 1999;10:723-31
   PubMed Web of Science ®Google Scholar
• Chesnoy S, Huang L. Structure and function of lipid-DNA complexes for gene delivery. Ann Rev Biophys Biomol Struct 2000;29:27-47
   PubMedGoogle Scholar
• Liu F, Shollenberger LM, Huang L. Non-immunostimulatory nonviral vectors. FASEB J 2004;18:1779-81
   PubMed Web of Science ®Google Scholar
• Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52
   PubMed Web of Science ®Google Scholar
• Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000;18:781-92
   PubMed Web of Science ®Google Scholar
• Khanna C, Lindblad-Toh K, Vail D, et al. The dog as a cancer model. Nat Biotechnol 2006;24:1065-66
   PubMed Web of Science ®Google Scholar
• Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 2005;16:937-46
   PubMed Web of Science ®Google Scholar
• Kamstock D, Guth A, Elmslie R, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2005
   Google Scholar
• Veir JK, Lappin MR, Dow SW. Evaluation of a novel mmunotherapy for treatment of chronic rhinitis in cats. J Feline Med Surg 2006;8:400-11
   PubMed Web of Science ®Google Scholar
• Johnson LR, Maggs DJ. Feline herpesvirus type-1 transcription is associated with increased nasal cytokine gene transcription in cats. Vet Microbiol 2005;108:225-33
   PubMed Web of Science ®Google Scholar
• Allison AC, Byars NE. Adjuvant formulations and their mode of action. Semin Immunol 1990;2:369-74
   PubMedGoogle Scholar
• Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005;54:1180-90
   PubMed Web of Science ®Google Scholar
• Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 2001;167:6462-70
   PubMed Web of Science ®Google Scholar
• Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003;21:3319-29
   PubMed Web of Science ®Google Scholar
• Gursel M, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 1999;17:1376-83
   PubMed Web of Science ®Google Scholar
• Latif N, Bachhawat BK. The effect of surface charges of liposomes in immunopotentiation. Biosci Rep 1984;4:99-107
   PubMed Web of Science ®Google Scholar
• Latif NA, Bachhawat BK. The effect of surface-coupled antigen of liposomes in immunopotentiation. Immunol Lett 1987;15:45-51
   PubMed Web of Science ®Google Scholar
• Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005;12:468-74
   PubMed Web of Science ®Google Scholar
• Zuhorn IS, Hoekstra D. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question? J Membr Biol 2002;189:167-79
   PubMed Web of Science ®Google Scholar
• Perrie Y, McNeil S, Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J Drug Target 2003;11:555-63
   PubMed Web of Science ®Google Scholar
• Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 2001;19:3301-10
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 1997;240:793-97
   PubMed Web of Science ®Google Scholar
• Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membrane Biol 2006;23:385-95
   PubMed Web of Science ®Google Scholar
• Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22:1903-13
   PubMed Web of Science ®Google Scholar
• Korsholm KS, Agger EM, Foged C, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007;121:216-26
   PubMed Web of Science ®Google Scholar
• Guy B, Pascal N, Francon A, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 2001;19:1794-805
   PubMed Web of Science ®Google Scholar
• Hattori Y, Kawakami S, Suzuki S, Yamashita F, Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun 2004;317:992-9
   PubMed Web of Science ®Google Scholar
• Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004;21:257-317
   PubMed Web of Science ®Google Scholar
• Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002;8:2782-7
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 2000;97:14590-5
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Hayashi A, Kunisawa J, et al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 2000;30:1740-7
   PubMed Web of Science ®Google Scholar
• Walker C, Selby M, Erickson A, Cataldo D, Valensi JP, Van Nest GV. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA 1992;89:7915-18
   PubMed Web of Science ®Google Scholar
• Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther 2007;9:45-52
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 2006;311:155-78
   PubMed Web of Science ®Google Scholar
• Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006;25:135-54
   PubMed Web of Science ®Google Scholar
• Kensil CR, Mo AX, Truneh A. Current vaccine adjuvants: an overview of a diverse class. Front Biosci 2004;9:2972-88
   PubMed Web of Science ®Google Scholar
• Dalpke A, Zimmermann S, Heeg K. Immunopharmacology of CpG DNA. Biol Chem 2002;383:1491-500
   PubMed Web of Science ®Google Scholar
• Jiao X, Wang RY, Qiu Q, Alter HJ, Shih JW. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004;85:1545-53
   PubMed Web of Science ®Google Scholar
• Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006;24:5119-32
   PubMed Web of Science ®Google Scholar
• Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006;36:3371-80
   PubMed Web of Science ®Google Scholar
• Molina MC, Armstrong TK, Zhang Y, Patel MM, Lentz YK, Anchordoquy TJ. The stability of lyophilized lipid/DNA complexes during prolonged storage. J Pharm Sci 2004;93:2259-73
   PubMed Web of Science ®Google Scholar
• Anchordoquy TJ, Allison SD, Molina MC, Girouard LG, Carson TK. Physical stabilization of DNA-based therapeutics. Drug Discov Today 2001;6:463-70
   PubMed Web of Science ®Google Scholar